Efficacy and safety of switching to dolutegravir/lamivudine in virologically suppressed people with HIV-1 aged ≥ 50 years: week 48 pooled results from the TANGO and SALSA studies

被引：0
|
作者：
Sharon Walmsley
Don E. Smith
Miguel Górgolas
Pedro E. Cahn
Thomas Lutz
Karine Lacombe
Princy N. Kumar
Brian Wynne
Richard Grove
Gilda Bontempo
Riya Moodley
Chinyere Okoli
Michelle Kisare
Bryn Jones
Andrew Clark
Mounir Ait-Khaled
机构：
[1] University Health Network,
[2] Albion Centre,undefined
[3] Fundación Jiménez Díaz,undefined
[4] Universidad Autónoma de Madrid,undefined
[5] Fundación Huésped,undefined
[6] Infektiologikum,undefined
[7] Hôpital Saint-Antoine,undefined
[8] Georgetown University Medical Center,undefined
[9] ViiV Healthcare,undefined
[10] GSK,undefined
[11] ViiV Healthcare,undefined
[12] ViiV Healthcare,undefined
来源：
AIDS Research and Therapy | / 21卷
关键词：
Aging; Comorbidity; DTG/3TC; HIV-1; Polypharmacy; Single-tablet regimen; Suppressed switch;  ≥ 50 years;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Efficacy and safety of switching to dolutegravir/lamivudine in virologically suppressed people with HIV-1 aged ≥ 50 years: week 48 pooled results from the TANGO and SALSA studies
    Walmsley, Sharon
    Smith, Don E.
    Gorgolas, Miguel
    Cahn, Pedro E.
    Lutz, Thomas
    Lacombe, Karine
    Kumar, Princy N.
    Wynne, Brian
    Grove, Richard
    Bontempo, Gilda
    Moodley, Riya
    Okoli, Chinyere
    Kisare, Michelle
    Jones, Bryn
    Clark, Andrew
    Ait-Khaled, Mounir
    [J]. AIDS RESEARCH AND THERAPY, 2024, 21 (01)
  • [2] Efficacy and safety of switching to dolutegravir/lamivudine in virologically suppressed PLHIV aged ≥50 years: pooled results from TANGO and SALSA
    Walmsley, Sharon
    Smith, Don E.
    Gorgolas, Miguel
    Cahn, Pedro E.
    Lutz, Thomas
    Lacombe, Karine
    Kumar, Princy N.
    Wynne, Brian
    Grove, Richard
    Bontempo, Gilda
    Moodley, Riya
    Spinelli, Frank
    Jones, Bryn
    Okoli, Chinyere
    Ait-Khaled, Mounir
    Bartholomaeus, Patrick
    [J]. HIV MEDICINE, 2023, 24 : 25 - 26
  • [3] Efficacy and safety of dolutegravir/lamivudine in virologically suppressed female participants: week 48 data from the pooled TANGO and SALSA studies
    Katlama, C.
    Bisshop, F.
    Bogner, J.
    Elias, M. J. Perez
    Di Giambenedetto, S.
    Clarke, E.
    Hodder, S.
    Nwokolo, N.
    Ait-Khaled, M.
    Oyee, J.
    Grove, R.
    Wynne, B.
    Okoli, C.
    Jones, B.
    Kisare, M.
    [J]. HIV MEDICINE, 2024, 25 (07) : 873 - 884
  • [4] Efficacy and Safety of Switching to Dolutegravir/Lamivudine (DTG/3TC) in Treatment-Experienced, Virologically Suppressed PLHIV Aged ≥50 Years: Pooled Results From the TANGO and SALSA Studies
    Walmsley, S.
    Smith, D. E.
    Gorgolas, M.
    Cahn, P. E.
    Lutz, T.
    Lacombe, K.
    Kumar, P. N.
    Wynne, B.
    Grove, R.
    Bontempo, G.
    Moodley, R.
    Spinelli, F.
    Jones, B.
    Okoli, C.
    Ait-Khaled, M.
    [J]. JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2022, 25 : 123 - 124
  • [5] Efficacy and Safety of Switching to Dolutegravir/Lamivudine in Virologically Suppressed People Living with HIV-1 Aged Over 65 Years
    Calza, Leonardo
    Colangeli, Vincenzo
    Legnani, Giorgio
    Cretella, Silvia
    Bon, Isabella
    Viale, Pierluigi
    [J]. AIDS RESEARCH AND HUMAN RETROVIRUSES, 2024, 40 (02) : 73 - 79
  • [6] Efficacy and safety of switching to dolutegravir/lamivudine by baseline regimen in virologically suppressed adults: 48-week pooled analysis
    Scholten, Stefan
    Cahn, Pedro
    Ruane, Peter
    Kaplan, Richard
    Portilla, Joaquin
    Hodder, Sally
    Bisshop, Fiona
    Wynne, Brian R.
    Grove, Richard
    Bontempo, Gilda
    Moodley, Riya
    Jones, Bryn
    Ait-Khaled, Mounir
    Okoli, Chinyere
    Fetscher, Harald
    [J]. HIV MEDICINE, 2023, 24 : 24 - 25
  • [7] Real-world effectiveness and safety of switching to dolutegravir/lamivudine among people living with HIV-1 aged over 50 years who are virologically suppressed
    Pineiro, C.
    Policarpo, S.
    Caldas, C.
    Santos, L.
    Augusto, I.
    Dimondi, V. P.
    Serrao, R.
    [J]. HIV MEDICINE, 2024,
  • [8] Dolutegravir/Lamivudine Efficacy and Safety Outcomes in People With HIV-1 With or Without Historical Resistance Results at Screening: 48-Week Pooled Analysis
    Scholten, Stefan
    Cahn, Pedro
    Portilla, Joaquin
    Bisshop, Fiona
    Hodder, Sally
    Ruane, Peter
    Kaplan, Richard
    Wynne, Brian R.
    Man, Choy Y.
    Grove, Richard
    Wang, Ruolan
    Jones, Bryn
    Ait-Khaled, Mounir
    Kisare, Michelle
    Okoli, Chinyere
    [J]. OPEN FORUM INFECTIOUS DISEASES, 2024, 11 (07):
  • [9] Efficacy and Safety of Two-Drug Regimens with Dolutegravir plus Rilpivirine or Lamivudine in HIV-1 Virologically Suppressed People Living with HIV
    Duenas-Gutierrez, Carlos
    Buzon, Luis
    Pedrero-Tome, Roberto
    Iribarren, Jose A.
    De los Santos, Ignacio
    De la Fuente, Sara
    Pousada, Guillermo
    Moran, Miguel Angel
    Moreno, Estela
    Ferreira, Eva
    Gomez, Julia
    Troya, Jesus
    [J]. VIRUSES-BASEL, 2023, 15 (04):
  • [10] Efficacy and safety of dolutegravir/lamivudine (DTG/3TC) in Black and Asian participants from TANGO and SALSA: pooled 48-week data analyzed by race
    Kumar, P.
    Hagins, D.
    Andrade-Villanueva, J.
    Lu, P.
    Adachi, E.
    Rubio, R.
    Lutz, T.
    Ait-Khaled, M.
    Grove, R.
    Wynne, B.
    Jones, B.
    Okoli, C.
    [J]. JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2022, 25 : 90 - 91
12345